Hormone replacement therapy: changes in prescribing practice

@article{Davies2019HormoneRT,
  title={Hormone replacement therapy: changes in prescribing practice},
  author={Melanie Davies and Haitham Hamoda},
  journal={BMJ},
  year={2019},
  volume={364}
}
Vinogradova and colleagues’ study is a welcome addition to the literature on the association between hormone replacement therapy (HRT) and risk of venous thromboembolism.1 The results are broadly in keeping with other research in this area, but this study provides greater detail about the potential risks of different HRT preparations, including the different types of oestrogen and progestogens, … 

References

SHOWING 1-4 OF 4 REFERENCES
Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
TLDR
Transdermal treatment was the safest type of hormone replacement therapy when risk of venous thromboembolism was assessed and appears to be underused, with the overwhelming preference still for oral preparations.
The British Menopause Society & Women’s Health Concern 2016 recommendations on hormone replacement therapy in menopausal women
TLDR
These recommendations provide updated guidance relating to the changes in clinical practice post-WHI including the cardiovascular ‘timing hypothesis’ and ‘window of opportunity’, the role of transdermal administration of estradiol as well as that of micronised progesterone in this context.
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
TLDR
In preparing these international recommendations, experts have taken into account geographical variations in medical care, prevalence of diseases, and country-specific attitudes of the public, medical community and health authorities towards menopause management.